Galectin Therapeutics to Present at the RedChip Small-Cap Equities Virtual Conference

Galectin Therapeutics to Present at the RedChip Small-Cap Equities Virtual Conference

<0> Galectin Therapeutics Inc.Maureen Foley, 617-559-0033Chief Operating Officer </0>

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it will present at the RedChip Small-Cap Equities Virtual Conference.

The Company’s presentation will be webcast live at on August 30, 2012, beginning at 10:30 AM Eastern time. To register for the conference, please visit . Please log on approximately 10 minutes before the start of the conference to ensure a timely connection.

Galectin Therapeutics will deliver a 30-minute corporate presentation. Investors will have the opportunity to speak with Company executives during a 15-minute question-and-answer session following the presentation. An archive of the presentation will be available in the Investor’s section of the Company’s website: .

Galectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. The Company is leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at .

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

Sean Harper and Beth Seidenberg tell FierceBiotech how and why they set up their own VC firm, Westlake Village BioPartners.

Imara is looking to cap a good 2019 with an initial public offering in 2020. The rare disease biotech wants $86 million on the Nasdaq.